Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized clopidogrel administration guided by CYP2C19 genotype and platelet activity in PCI patients
ChiCTR-OPC-17011769Phase 4Recruiting
- Sponsor
- Medical Ethics Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clopidogrel and ticagrelor in coronary arteriosclerosis, sponsored by Medical Ethics Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital. Primary endpoints: CYP2C19 genotype classification and Maximum platelet aggregation rate (AA/ADP). Started Aug 2016; status: recruiting.
02
Drugs
clopidogrelticagrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR-OPC-17011769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011769.